Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: Validation from therapeutic outcomes

Liver International

Volumn 31, Issue 7, 2011, Pages 1028-1038

  Pattullo, Venessa ^a,b   McAndrews, Mary Pat ^a   Damyanovich, Andrei ^c   Heathcote, E Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b University of Sydney   (Australia)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chronic hepatitis C; Health related quality of life; Magnetic resonance spectroscopy; Mood; Neurocognitive tests

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FATIGUE; FEMALE; FOLLOW UP; GLOBUS PALLIDUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RISK FACTOR; SHORT FORM 36; TREATMENT OUTCOME; VIRAL CLEARANCE;

ASPARTIC ACID; BRAIN; COGNITION DISORDERS; COHORT STUDIES; CREATINE; FATIGUE; FEMALE; GLOBUS PALLIDUS; HEPATITIS C, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 79960097138     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02549.x     Document Type: Article

References (28)

1. Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600-8.
2. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasi species in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78: 5170-83.
3. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009; 83: 1312-9.
4. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-9.
5. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-51.
6. Forton DM, Hamilton G, Allsop JM, et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol 2008; 49: 316-22.
7. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-8.
8. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005; 77: 90-100.
9. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-9.
10. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
11. Helbling B, Overbeck K, Gonvers JJ, et al. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57: 1597-603.
12. Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 1154-63.
13. Thein HH, Maruff P, Krahn MD, et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 2007; 8: 520-8.
14. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-5.
15. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-70.
16. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-7.
17. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
18. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
19. Teixeira MC, Ribeiro Mde F, Gayotto LC, Chamone Dde A, Strauss E. Worse quality of life in volunteer blood donors with hepatitis C. Transfusion 2006; 46: 278-83.
20. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
21. Taylor MJ, Letendre SL, Schweinsburg BC, et al. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. J Int Neuropsychol Soc 2004; 10: 110-3.
22. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38-9.
23. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-14.
24. Pham TN, Michalak TI. Hepatitis C virus in peripheral blood mononuclear cells of individuals with isolated anti-hepatitis C virus antibody reactivity. Hepatology 2008; 48: 350-1; author reply 351-352.
25. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 2009; 49: 1431-4.
26. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007; 14: 1189-97.
27. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 2006; 19: 358-61.
28. Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001; 36: 156-64.